Meanwhile, LAG-3, as an NK cell-associated immune checkpoint, targeted inhibition of its expression is beneficial for enhancing NK cell activity, and MM-related clinical treatment studies targeting this feature are currently underway [63]. This evidence concerns the gene LAG3 and Miyoshi myopathy.